공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

기면증 : 시장 인사이트, 역학, 시장 예측(-2030년)

Narcolepsy Market Insight, Epidemiology and Market Forecast -2030

리서치사 DelveInsight Business Research LLP
발행일 On Demand Report 상품 코드 980938
페이지 정보 영문 156 Pages
가격
US $ 6,950 ₩ 8,062,000 PDF (Single User License)
US $ 13,900 ₩ 16,125,000 PDF (Site License)
US $ 20,850 ₩ 24,188,000 PDF (Global License)


기면증 : 시장 인사이트, 역학, 시장 예측(-2030년) Narcolepsy Market Insight, Epidemiology and Market Forecast -2030
발행일 : On Demand Report 페이지 정보 : 영문 156 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 주요 7개국(미국, 유럽 주요 5개국(EU5 : 프랑스, 독일, 이탈리아, 스페인, 영국), 일본)의 기면증 역학 동향과 향후 시장 전망에 대해 분석했으며, 질환 개요, 시장의 기본 구조, 현재 치료법과 충족되지 않은 욕구, 환자수 동향 전망, 출시/임상시험 중인 치료제 개요, 세계 전체/국가별 시장 규모(과거 3년간, 향후 11년간), 주요 시장 성장 촉진요인 및 억제요인 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 인사이트

제2장 기면증 : 개요

제3장 기면증 경쟁 정보 분석

제4장 기면증 : 역학 개요

  • 환자 점유율(2017년)
  • 환자 점유율(2030년)

제5장 기면증 : 시장 개요

  • 시장 점유율 구조(2017년)
  • 시장 점유율 구조(2030년)

제6장 기면증 : 질환 개요

  • 서론
  • 징후와 증상
  • 합병증
  • 병태생리
  • 병인
  • 위험요인
  • 진단 방법

제7장 역학과 환자 인구

  • 분석 포인트
  • 환자 인구와 예측 지표

제8장 기면증 : 주요 7개국의 환자수

  • 미국
    • 진찰 환자수
    • 발증 건수 : 하위 타입별
    • 기면증에 관련된 임상 증상
    • 기면증 유병률 : 연령층별
  • 독일
    • 진찰 환자수
    • 발증 건수 : 하위 타입별
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
    • 진찰 환자수
    • 발증 건수 : 하위 타입별
  • 일본

제9장 치료와 관리

  • 가이드라인과 관리 방법 : 지역별

제10장 충족되지 않은 욕구

제11장 출시 제품

  • Provogil : Cephalon Inc.
    • 약물 설명
    • 규제 마일스톤
    • 제품 개요
  • Xyrem : Jazz Pharmaceuticals
    • 제품 개요
    • 장단점
  • JZP-258 : Jazz Pharmaceuticals Inc.
    • 임상시험 동향
  • JZP-110 : Jazz Pharmaceuticals

제12장 기타 기면증 치료제

  • Anafranil (clomipramine)
    • 제품 개요
    • 규제 마일스톤
    • 장단점
  • Prozac (Fluoxetine)
    • 제품 개요
  • Prozac (Fluoxetine)
  • Tofranil (Imipramine)
  • Vivactil (Protriptyline)
  • Zoloft (Sertraline)
  • Effexor (Venlafaxine)
  • Desoxyn (Methamphetamine)
  • NUVIGIL
  • Wakix (Pitolisant)
  • Ritalin
  • Dexedrine
  • Adderall
  • Atomoxetine

제13장 신약

  • Sodium oxybate ER: Avadel Pharmaceuticals
    • 제품 개요
    • 규제 마일스톤
    • 임상 개발
    • 안전성과 유효성
    • 제품 개요
  • AXS-12 (Reboxetine) : Axsome Therapeutics

제14장 기타 유망한 후보의약품

  • SUVN-G3031 : Suven Life Sciences Limited
    • 제품 설명
    • 임상 개발
    • 안전성과 유효성
  • TAK-994 : Takeda
  • TAK-925 : Takeda
    • 제품 설명
  • ADAIR : Vallon Pharmaceuticals
  • Mazindol CR: NLS Pharma
    • 제품 개발 활동
    • 제품 개요

제15장 임상시험 개발이 보고되지 않은 제품

  • BTD-001 : Balance Therapeutics
    • 제품 설명
    • 임상 개발
    • 임상시험 정보
    • 제품 개요
  • TS-091 : Taisho Pharmaceutical Co
  • THN102 (Modafinil + Flecainide): Theranexus
    • 규제 마일스톤

제16장 기면증 : 주요 7개국 시장 분석

  • 분석 포인트
  • 주요 7개국의 기면증 시장 규모

제17장 주요 7개국 : 기면증 시장 전망

제18장 국가별 시장 분석

  • 미국
    • 기면증 전체 시장 규모
    • 시장 규모 : 치료제별
  • 유럽 5개국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
  • 일본

제19장 시장 성장 촉진요인

제20장 시장 성장 저해요인

제21장 부록

제22장 DelveInsight의 서비스 내용

제23장 면책사항

제24장 DelveInsight에 대해

LSH 21.01.21

List of Tables

  • Table 1: Summary of Narcolepsy, Epidemiology, and Key Events (2017-2030)
  • Table 2:Total Prevalent Patient Population of Narcolepsy in the 7MM (2017-2030)
  • Table 3: Prevalent Cases of Narcolepsy in the United States (2017-2030)
  • Table 4: Subtype-specific cases of Narcolepsy in the United States (2017-2030)
  • Table 5: Clinical Manifestations associated with Narcolepsy in the United States (2017-2030)
  • Table 6: Age-group wise Prevalence of Narcolepsy (2017-2030)
  • Table 7: Prevalent Cases of Narcolepsy in Germany (2017-2030)
  • Table 8: Subtype-specific cases of Narcolepsy in Germany (2017-2030)
  • Table 9:Clinical Manifestations associated with Narcolepsy in Germany (2017-2030)
  • Table 10: Age-group wise Prevalence of Narcolepsy (2017-2030)
  • Table 11: Prevalent Cases of Narcolepsy in France (2017-2030)
  • Table 12: Subtype-specific cases of Narcolepsy in France (2017-2030)
  • Table 13: Clinical Manifestations associated with Narcolepsy in France (2017-2030)
  • Table 14: Age-group wise Prevalence of Narcolepsy (2017-2030)
  • Table 15: Prevalent Cases of Narcolepsy in Italy (2017-2030)
  • Table 16:Subtype-specific cases of Narcolepsy in Italy (2017-2030)
  • Table 17: Clinical Manifestations associated with Narcolepsy in Italy (2017-2030)
  • Table 18: Age-group wise Prevalence of Narcolepsy (2017-2030)
  • Table 19: Prevalent Cases of Narcolepsy in Spain (2017-2030)
  • Table 20: Subtype-specific cases of Narcolepsy in Spain (2017-2030)
  • Table 21: Clinical Manifestations associated with Narcolepsy in Spain (2017-2030)
  • Table 22: Age-group wise Prevalence of Narcolepsy (2017-2030)
  • Table 23: Prevalent Cases of Narcolepsy in the United Kingdom (2017-2030)
  • Table 24:Subtype-specific cases of Narcolepsy in the United Kingdom (2017-2030)
  • Table 25: Clinical Manifestations associated with Narcolepsy in the United Kingdom (2017-2030)
  • Table 26: Age-group wise Prevalence of Narcolepsy (2017-2030)
  • Table 27: Prevalent Cases of Narcolepsy in Japan (2017-2030)
  • Table 28: Subtype-specific cases of Narcolepsy in Japan (2017-2030)
  • Table 29: Clinical Manifestations associated with Narcolepsy in Japan (2017-2030)
  • Table 30: Age-group wise Prevalence of Narcolepsy in Japan (2017-2030)
  • Table 31: Sodium oxybate, Clinical Trial Description
  • Table 32: AXS-12, Clinical Trial Description
  • Table 33: BTD-001 Clinical Trial Description
  • Table 34: TS-091 Clinical Trial Description
  • Table 35: THN102 Clinical Trial Description
  • Table 36: 7 Major Market Size of Narcolepsy in USD million (2017-2030)
  • Table 37: Market Size of Narcolepsy in the United States, USD million (2017-2030)
  • Table 38: Therapy-based Market Size of Narcolepsy in the US, in USD million (2017-2030))
  • Table 39: Market Size of Narcolepsy in Germany, in USD million (2017-2030)
  • Table 40: Therapy-based Market Size of Narcolepsy in Germany, in USD million (2017-2030))
  • Table 41: Market Size of Narcolepsy in France, in USD million (2017-2030)
  • Table 42: Therapy-based Market Size of Narcolepsy in France, in USD million (2017-2030)
  • Table 43: Market Size of Narcolepsy in Italy, in USD million (2017-2030)
  • Table 44: Therapy-based Market Size of Narcolepsy in Italy, in USD million (2017-2030))
  • Table 45: Market Size of Narcolepsy in Spain, in USD million (2017-2030)
  • Table 46: Therapy-based Market Size of Narcolepsy in Spain, in USD million (2017-2030))
  • Table 47: Market Size of Narcolepsy in the UK, in USD million (2017-2030)
  • Table 48: Therapy-based Market Size of Narcolepsy in the UK, in USD million (2017-2030))
  • Table 49: Market Size of Narcolepsy in Japan, in USD million (2017-2030)
  • Table 50: Therapy-based Market Size of Narcolepsy in in Japan, in USD million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Complications of Narcolepsy
  • Figure 3: Pathophysiology of Narcolepsy
  • Figure 4: Prevalent Cases of Narcolepsy in the 7MM (2017-2030)
  • Figure 5: Diagnosed Prevalent Cases of Narcolepsy in the United States (2017-2030)
  • Figure 6: Subtype-specific cases of Narcolepsy in the United States (2017-2030)
  • Figure 7: Clinical Manifestations associated with Narcolepsy in the United States (2017-2030)
  • Figure 8: Age-group wise Prevalence of Narcolepsy (2017-2030)
  • Figure 9: Diagnosed Prevalent Cases of Narcolepsy in Germany (2017-2030)
  • Figure 10: Subtype-specific cases of Narcolepsy in Germany (2017-2030)
  • Figure 11: Clinical Manifestations associated with Narcolepsy in Germany (2017-2030)
  • Figure 12: Age-group wise Prevalence of Narcolepsy (2017-2030)
  • Figure 13: Diagnosed Prevalent Cases of Narcolepsy in France (2017-2030)
  • Figure 14: Subtype-specific cases of Narcolepsy in France (2017-2030)
  • Figure 15: Clinical Manifestations associated with Narcolepsy in France (2017-2030)
  • Figure 16: Age-group wise Prevalence of Narcolepsy (2017-2030)
  • Figure 17: Diagnosed Prevalent Cases of Narcolepsy in Italy (2017-2030)
  • Figure 18: Subtype-specific cases of Narcolepsy in Italy (2017-2030)
  • Figure 19: Clinical Manifestations associated with Narcolepsy in Italy (2017-2030)
  • Figure 20: Age-group wise Prevalence of Narcolepsy (2017-2030)
  • Figure 21: Diagnosed Prevalent Cases of Narcolepsy in Spain (2017-2030)
  • Figure 22: Subtype-specific cases of Narcolepsy in Spain (2017-2030)
  • Figure 23: Clinical Manifestations associated with Narcolepsy in Spain (2017-2030)
  • Figure 24: Age-group wise Prevalence of Narcolepsy (2017-2030)
  • Figure 25: Diagnosed Prevalent Cases of Narcolepsy in the United Kingdom (2017-2030)
  • Figure 26: Subtype-specific cases of Narcolepsy in the United Kingdom (2017-2030)
  • Figure 27: Clinical Manifestations associated with Narcolepsy in the United Kingdom (2017-2030)
  • Figure 28: Age-group wise Prevalence of Narcolepsy (2017-2030)
  • Figure 29: Diagnosed Prevalent Cases of Narcolepsy in Japan (2017-2030)
  • Figure 30: Subtype-specific cases of Narcolepsy in Japan (2017-2030)
  • Figure 31: Clinical Manifestations associated with Narcolepsy in Japan (2017-2030)
  • Figure 32: Age-group wise Prevalence of Narcolepsy (2017-2030)
  • Figure 33: Decision tree for starting and then adapting the therapy for excessive daytime sleepiness and cataplexy
  • Table 34: Therapies for the treatment of Excessive daytime sleepiness and irresistible episodes of sleep with Narcolepsy
  • Figure 35: Non pharmacological treatment practices for Narcolepsy
  • Figure 36: Unmet Needs for Narcolepsy
  • Figure 37: 7 Major Market Size of Narcolepsy in USD million (2017-2030)
  • Figure 38: Market Size of Narcolepsy in the US, in USD million (2017-2030)
  • Figure 39: Therapy-based Market Size of Narcolepsy in the US, in USD million (2017-2030)
  • Figure 40: Market Size of Narcolepsy in Germany, USD millions (2017-2030)
  • Figure 41: Therapy-based Market Size of Narcolepsy in Germany, in USD million (2017-2030)
  • Figure 42: Market Size of Narcolepsy in France, in USD million (2017-2030)
  • Figure 43: Therapy-based Market Size of Narcolepsy in France, in USD million (2017-2030)
  • Figure 44: Market Size of Narcolepsy in Italy, in USD million (2017-2030)
  • Figure 45: Therapy-based Market Size of Narcolepsy in Italy, in USD million (2017-2030)
  • Figure 46: Market Size of Narcolepsy in Spain, in USD million (2017-2030)
  • Figure 47: Therapy-based Market Size of Narcolepsy in Spain, in USD million (2017-2030)
  • Figure 48: Market Size of Narcolepsy in the UK, USD millions (2017-2030)
  • Figure 49: Therapy-based Market Size of Narcolepsy in the UK, in USD million (2017-2030)
  • Figure 50: Market Size of Narcolepsy in Japan, in USD million (2017-2030)
  • Figure 51: Therapy-based Market Size of Narcolepsy in Japan, in USD million (2017-2030)
  • Figure 52: Market Drivers
  • Figure 53:Market Barriers

DelveInsight's 'Narcolepsy-Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Narcolepsy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Narcolepsy market report provides analysis regarding current treatment practices, marketed drugs like Provigil, Xyrem, JZP-258, JZP-110 etc., emerging therapies like FT-218, AXS-12 and other promising candidates like SUVN-G3031, TAK-994, TAK-925, market share of the individual therapies, and historical, current and forecasted Narcolepsy market size from 2017 to 2030, segmented by seven major markets.

The report also covers current Narcolepsy treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Narcolepsy - Disease Understanding and Treatment Algorithm

Overview:

Narcolepsy is a chronic neurological/brain disorder which involves poor control of sleep and wakefulness. Narcolepsy is classically a tetrad of symptoms including EDS, cataplexy, sleep paralysis, and hypnagogic hallucinations. People suffering from narcolepsy experience periods of excessive daytime sleepiness and sudden uncontrollable episodes of falling asleep during any time of the day.

According to ICSD-III(International Classification of Sleep Disorders-third edition), Narcolepsy is classified as distinct central nervous system hypersomnia in narcolepsy type 1 (NT1), formerly Narcolepsy with cataplexy caused by a selective loss of hypothalamic neurons producing hypocretin, and narcolepsy type 2 (NT2), formerly Narcolepsy without cataplexy and with normal hypocretin levels.

Narcolepsy can be diagnosed by using several tests and techniques such as physical examination, exhaustive medical history and tests that are considered essential in confirming a diagnosis of Narcolepsy are the polysomnogram (PSG) and the multiple sleep latency test.

Treatment:

There is no curative therapy for Narcolepsy till date, and current recommended therapies in Narcolepsy are limited to symptomatic treatment, targeting the main symptoms of the disease, depending on their severity. Behavioral and psychosocial interventions also impact the clinical outcomes of patients significantly. Various therapies have been approved by the USFDA and EMA as first and second-line treatment options for Narcolepsy.

This chapter covers the details of conventional and current medical therapies available for the treatment of Narcolepsy. It also provides Narcolepsy treatment guidelines across the United States and Europe.

DelveInsight's Narcolepsy market report gives a thorough understanding of the disease by including details such as disease definition, etiology, types, neurobiology, biomarkers and diagnosis. It also provides Narcolepsy treatment pattern and treatment guidelines in the US and Europe.

Epidemiology:

The Narcolepsy epidemiology chapters provide insights about historical and current Narcolepsy patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Narcolepsy epidemiology is segmented by the diagnosed prevalent cases of Narcolepsy, subtype-specific cases of Narcolepsy, clinical manifestations associated with Narcolepsy and age-group wise prevalence of Narcolepsy. Besides, the report includes a thorough analysis of all segments.

According to DelveInsight's , the total prevalent population of Narcolepsy in seven major markets was 499,888 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, total prevalent cases for Narcolepsy were highest in Japan, followed by the United States and Germany. France accounted for the least number of prevalent cases among the 7MM.

Drug Chapters:

This segment encloses the detailed analysis of the drugs in the Narcolepsy pipeline. It also helps understand the Narcolepsy clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

The first-line care of a patient with SCI involves securing the airway, breathing, and circulation, followed by appropriate spinal immobilization in the field to limit further insult of the highly susceptible cord during transport. Emerging therapies like MC001, AST-OPC1, KP-100IT, Elezanumab and Stemirac are expected to bring a positive shift to the overall market.

Market Outlook:

The market size of Narcolepsy is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest Narcolepsy market size. Among the EU5 countries, Germany had the largest market size, with USD 131.90 million, followed by the United Kingdom with USD 87.93 million in 2017. Italy had the smallest market size of Narcolepsy, with USD 14.66 million in 2017.

Drugs Uptake:

This section focuses on the rate of uptake of the potential drugs in the Narcolepsy market or expected to get launched in the market during the study period 2017-2030. The analysis covers Narcolepsy market uptake by drugs; patient uptake by therapies; and sale of each drug.

It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of Narcolepsy market is anticipated to experience a major positive shift in the coming years owing to the expected launch of therapies like FT-218 and AXS-12.

Narcolepsy: Pipeline Development Activities

The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.

Pipeline Development Activities:

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Narcolepsy.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Narcolepsy domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We have performed the competitive and market Intelligence analysis of the Narcolepsy Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.

Report Highlights::

  • In the coming years, Narcolepsy market scenario is expected to experience a positive shift across the 7MM due to a robust pipeline.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Narcolepsy Report Insights:

  • Patient Population
  • Therapeutic Approaches
  • Narcolepsy Pipeline Analysis
  • Narcolepsy Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Narcolepsy Report Key Strengths:

  • 11 years Forecast
  • 7MM Coverage
  • Narcolepsy Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Narcolepsy Report Assessment:

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Narcolepsy market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Narcolepsy total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Narcolepsy market size during the forecast period (2017-2030)?
  • At what CAGR, the Narcolepsy market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Narcolepsy market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Narcolepsy market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden and unmet needs of Narcolepsy?
  • What is the historical Narcolepsy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Narcolepsy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Narcolepsy?
  • Out of all 7MM countries, which country would have the highest prevalent population of Narcolepsy during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for Narcolepsy treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Narcolepsy in the USA, Europe, and Japan?
  • How many companies are developing therapies for the treatment of Narcolepsy?
  • How many therapies are developed by each company for Narcolepsy?
  • How many are emerging therapies in mid-stage, and late stage of development for Narcolepsy treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Narcolepsy therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Narcolepsy and their status?
  • What are the key designations that have been granted for the emerging therapies for Narcolepsy?
  • What is the global historical and forecasted market of Narcolepsy?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Narcolepsy market
  • To understand the future market competition in the Narcolepsy market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Narcolepsy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Narcolepsy market
  • To understand the future market competition in the Narcolepsy market

Which geography accounted for the largest Narcolepsy market size?

The United States accounted for the largest Narcolepsy market size.

What is forecasted Narcolepsy size in 2030?

DelveInsight estimates an increase in Narcolepsy Market Size during the study period, 2017-2030

What are the present Narcolepsy market drivers?

Shortcomings associated with existing treatment, active clinical pipeline, increasing prevalence of disease

What are the Narcolepsy market barriers?

Need for better treatment practices, Hurdles in treatment selection, Identification of initial symptoms

How many companies are developing drugs for Narcolepsy?

Currently, two key pharma players are developing the drug for Narcolepsy

Which are the leading companies in Narcolepsy market?

Key Players - Avadel Pharmaceuticals, Axsome Therapeutics

How is epidemiology segmented for Narcolepsy?

Diagnosed prevalent cases of Narcolepsy, subtype-specific cases of Narcolepsy, clinical manifestations associated with Narcolepsy and age-group wise prevalence of Narcolepsy

Table of Contents

1 Key Insights

2 Executive Summary of Narcolepsy

3 SWOT Analysis for Narcolepsy

4 Narcolepsy Epidemiology Overview at a Glance

  • 4.1 Patient Share (%) Distribution of Narcolepsy in 2017
  • 4.2 Patient Share (%) Distribution of Narcolepsy in 2030

5 Narcolepsy Market Overview at a Glance

  • 5.1 Market Share (%) Distribution of Narcolepsy in 2017
  • 5.2 Market Share (%) Distribution of Narcolepsy in 2030

6 Disease Background and Overview: Narcolepsy

  • 6.1 Introduction
  • 6.2 Signs and Symptoms
  • 6.3 Complications
  • 6.4 Pathophysiology
  • 6.5 Etiology
  • 6.6 Risk Factors
  • 6.7 Diagnosis

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 Population and Forecast Parameters

8 7MM Total Prevalent Patient Population of Narcolepsy

  • 8.1 The United States
    • 8.1.1 Diagnosed Prevalent Patient Population of Narcolepsy in the United States
    • 8.1.2 Subtype-specific cases of Narcolepsy in the United States
    • 8.1.3 Clinical Manifestations associated with Narcolepsy
    • 8.1.4 Age-group wise Prevalence of Narcolepsy
  • 8.2 Germany
    • 8.2.1 Diagnosed Prevalent Patient Population of Narcolepsy in Germany
    • 8.2.2 Subtype-specific cases of Narcolepsy in Germany
    • 8.2.3 Clinical Manifestations associated with Narcolepsy
    • 8.2.4 Age-group wise Prevalence of Narcolepsy
  • 8.3 France
    • 8.3.1 Diagnosed Prevalent Patient Population of Narcolepsy in France
    • 8.3.2 Subtype-specific cases of Narcolepsy in France
    • 8.3.3 Clinical Manifestations associated with Narcolepsy
    • 8.3.4 Age-group wise Prevalence of Narcolepsy
  • 8.4 Italy
    • 8.4.1 Diagnosed Prevalent Patient Population of Narcolepsy in Italy
    • 8.4.2 Subtype-specific cases of Narcolepsy in Italy
    • 8.4.3 Clinical Manifestations associated with Narcolepsy
    • 8.4.4 Age-group wise Prevalence of Narcolepsy
  • 8.5 Spain
    • 8.5.1 Diagnosed Prevalent Patient Population of Narcolepsy in Spain
    • 8.5.2 Subtype-specific cases of Narcolepsy in Spain
    • 8.5.3 Clinical Manifestations associated with Narcolepsy
    • 8.5.4 Age-group wise Prevalence of Narcolepsy
  • 8.6 United Kingdom
    • 8.6.1 Diagnosed Prevalent Patient Population of Narcolepsy in the United Kingdom
    • 8.6.2 Subtype-specific cases of Narcolepsy in the United Kingdom
    • 8.6.3 Clinical Manifestations associated with Narcolepsy
    • 8.6.4 Age-group wise Prevalence of Narcolepsy
  • 8.7 Japan
    • 8.7.1 Diagnosed Prevalent Patient Population of Narcolepsy in Japan
    • 8.7.2 Subtype-specific cases of Narcolepsy in Japan
    • 8.7.3 Clinical Manifestations associated with Narcolepsy
    • 8.7.4 Age-group wise Prevalence of Narcolepsy

9 Treatment and Management

  • 9.1 Guideline and Management
    • 9.1.1 American Academy of Sleep Medicine Guidelines
    • 9.1.2 European Federation of Neurological Societies (EFNS) Guidelines

10 Unmet Needs

11 Marketed Products

  • 11.1 Provogil: Cephalon Inc.
    • 11.1.1 Drug Description
    • 11.1.2 Regulatory Milestones
    • 11.1.3 Product Profile
  • 11.2 Xyrem: Jazz Pharmaceuticals
    • 11.2.1 Product Description
    • 11.2.2 Regulatory Milestones
    • 11.2.3 Advantages and Disadvantages
    • 11.2.4 Product Profile
  • 11.3 JZP-258: Jazz Pharmaceuticals Inc.
    • 11.3.1 Drug Description
    • 11.3.2 Regulatory Milestones
    • 11.3.3 Clinical Development
    • 11.3.6 Product Profile
  • 11.4 JZP-110: Jazz Pharmaceuticals
    • 11.4.1 Product Description
    • 11.4.2 Regulatory Milestones
    • 11.4.3 Product Profile

12 Other Narcoleptics

  • 12.1 Anafranil (clomipramine)
    • 12.1.1 Product Description
    • 12.1.2 Regulatory Milestones
    • 12.1.3 Advantages and Disadvantages
  • 12.2 Desipramine
    • 12.2.1 Product Description
    • 12.2.2 Regulatory Milestones
    • 12.2.3 Advantages and Disadvantages
    • 12.2.4 Product Profile
  • 12.3 Prozac (Fluoxetine)
    • 12.3.1 Product Description
    • 12.3.2 Regulatory Milestones
    • 12.3.3 Advantages and Disadvantages
    • 12.3.4 Product Profile
  • 12.4 Tofranil (Imipramine)
    • 12.4.1 Product Description
    • 12.4.2 Advantages and Disadvantages
    • 12.4.3 Product Profile
  • 12.5 Vivactil (Protriptyline)
    • 12.5.1 Product Description
    • 12.5.2 Regulatory Milestones
    • 12.5.3 Advantages and Disadvantages
    • 12.5.4 Product Profile
  • 12.6 Zoloft (Sertraline)
    • 12.6.1 Product Description
    • 12.6.2 Regulatory Milestones
    • 12.6.3 Advantages and Disadvantages
    • 12.6.4 Product Profile
  • 12.7 Effexor (Venlafaxine)
    • 12.7.1 Product Description
    • 12.7.2 Regulatory Milestones
    • 12.7.3 Advantages and Disadvantages
    • 12.7.4 Product Profile
  • 12.8 Desoxyn (Methamphetamine)
    • 12.8.1 Product Description
    • 12.8.2 Regulatory Milestones
    • 12.8.3 Advantages and Disadvantages
    • 12.8.4 Product Profile
  • 12.9 NUVIGIL
    • 12.9.1 Product Description
    • 12.9.2 Regulatory Milestones
    • 12.9.3 Advantages and Disadvantages
    • 12.9.4 Product Profile
  • 12.1 Wakix (Pitolisant)
    • 12.10.1 Product Description
    • 12.10.2 Regulatory Milestones
    • 12.10.3 Advantages and Disadvantages
    • 12.10.4 Product Profile
  • 12.11 Ritalin
    • 12.11.1 Product Description
    • 12.11.2 Regulatory Milestones
    • 12.11.3 Advantages and Disadvantages
    • 12.11.4 Product Profile
  • 12.12 Dexedrine
    • 12.12.1 Product Description
    • 12.12.2 Regulatory Milestones
    • 12.12.3 Advantages and Disadvantages
    • 12.12.4 Product Profile
  • 12.13 Adderall
    • 12.13.1 Product Description
    • 12.13.2 Regulatory Milestones
    • 12.13.3 Advantages and Disadvantages
    • 12.13.4 Product Profile
  • 12.14 Atomoxetine
    • 12.14.1 Product Description
    • 12.14.2 Regulatory Milestones
    • 12.14.3 Advantages and Disadvantages
    • 12.14.4 Product Profile

13 Emerging Drugs

  • 13.1 Sodium oxybate ER: Avadel Pharmaceuticals
    • 13.1.1 Product Description
    • 13.1.2 Regulatory Milestones
    • 13.1.3 Clinical Development
    • 13.1.4 Safety and efficacy
    • 13.1.5 Product Profile
  • 13.2 AXS-12 (Reboxetine): Axsome Therapeutics
    • 13.2.1 Product Description
    • 13.2.2 Regulatory Milestones
    • 13.2.3 Clinical Development
    • 13.2.4 Safety and efficacy
    • 13.2.5 Product Profile

14 Other Promising Candidates

  • 14.1 SUVN-G3031: Suven Life Sciences Limited
    • 14.1.1 Product description
    • 14.1.2 Clinical Development
    • 14.1.3 Safety and Efficacy
  • 14.2 TAK-994: Takeda
    • 14.2.1 Product description
    • 14.2.2 Clinical Development
  • 14.3 TAK-925: Takeda
    • 14.3.1 Product Description
    • 14.3.2 Clinical Development
    • 14.3.3 Safety and Efficacy
  • 14.4 ADAIR: Vallon Pharmaceuticals
    • 14.4.1 Product Description
    • 14.4.2 Clinical Development
    • 14.4.3 Safety and Efficacy
  • 14.5 Mazindol CR: NLS Pharma
    • 14.5.1 Product Description
    • 14.5.2 Product Development Activities
    • 14.5.3 Product Profile

15 No Development Reported

  • 15.1 BTD - 001: Balance Therapeutics
    • 15.1.1 Product Description
    • 15.1.2 Clinical Development
    • 15.1.3 Clinical Trial Information
    • 15.1.4 Product Profile
  • 15.2 TS-091: Taisho Pharmaceutical Co
    • 15.2.1 Product Description
    • 15.2.2 Clinical Development
    • 15.2.3 Product Profile
  • 15.3 THN102 (Modafinil + Flecainide): Theranexus
    • 15.3.1 Regulatory Milestones
    • 15.3.2 Clinical Development
    • 15.3.3 Clinical Trial Information
    • 15.3.4 Product Profile

16 Narcolepsy: 7 Major Market Analysis

  • 16.1 Key Findings
  • 16.2 Market Size of Narcolepsy in 7MM

17 7MM: Narcolepsy Market Outlook

18 Country-wise Market Analysis

  • 18.1 The United States
    • 18.1.1 Total Market size of Narcolepsy in the U.S.
    • 18.1.2 Therapy-based market size of Narcolepsy in the U.S.
  • 18.2 EU-5 Countries
    • 18.2.1 Germany
    • 18.2.2 France
    • 18.2.3 Italy
    • 18.2.4 Spain
    • 18.2.5 United Kingdom
  • 18.3 Japan
    • 18.3.1 Total Market size of Narcolepsy in Japan
    • 18.3.2 Therapy-based market size of Narcolepsy in Japan

19 Market Drivers

20 Market Barriers

21 Appendix

  • 21.1 Report Methodology

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

Back to Top
전화 문의
F A Q